SEARCH:   Advanced

Blood, 22 October 2009, Vol. 114, No. 17, pp. 3677-3683. Prepublished online as a Blood First Edition Paper on August 17, 2009; DOI 10.1182/blood-2009-06-225706. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2009-06-225706v1 114/17/3677    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Kleinman, S. H. Articles by Busch, M. P. PubMed PubMed Citation Articles by Kleinman, S. H. Articles by Busch, M. P. Related Collections Transfusion Medicine Free Research Articles Red Cells, Iron, and Erythropoiesis Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSFUSION MEDICINE A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion Steven H. Kleinman1,2, Simone A. Glynn3, Tzong-Hae Lee4, Leslie H. Tobler4, Karen S. Schlumpf1, Deborah S. Todd1, Hannah Qiao1, Mei-ying W. Yu5, Michael P. Busch4,6, for the National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II (NHLBI REDS-II) 1 Westat Inc, Rockville, MD; 2 Department of Pathology, University of British Columbia, Vancouver, BC; 3 National Heart, Lung, and Blood Institute, Rockville, MD; 4 Blood Systems Research Institute, San Francisco, CA; 5 Division of Hematology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD; and 6 Department of Laboratory Medicine, University of California, San Francisco Parvovirus B19V infection can be a serious infection for hematology patients with underlying hemolysis or compromised erythropoiesis syndromes. Although case reports of B19V transmission by blood component transfusion (as contrasted to manufactured plasma derivatives) are rare, no studies have systematically determined a rate of transmission to recipients transfused with B19V DNA–positive components. We used a linked donor and recipient repository and a sensitive, quantitative B19V DNA polymerase chain reaction (PCR) assay to assess such transmission in B19V-susceptible (ie, anti-B19V immunoglobulin G [IgG] negative) recipients. We assessed 112 B19V DNA–positive components from 105 donors (of 12 529 tested donations) transfused into a population of surgical patients with a pretransfusion B19V IgG seroprevalence of 78%. We found no transmission to 24 susceptible recipients from transfusion of components with B19V DNA at concentrations less than 106 IU/mL (upper 95% confidence interval, 11.7%). We found an anamnestic IgG response in one pretransfusion seropositive recipient transfused with a component containing greater than 1010 IU/mL B19V DNA. These findings show either that transmission from components with less than 106 IU/mL does not occur, or, if it does, it is an uncommon event. These data do not support the need to routinely screen blood donations with a sensitive B19V DNA nucleic acid assay. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Transfused B19V: B-nign, B-ware, B-gone? Harvey G. Klein Blood 2009 114: 3509-3511. [Full Text] [PDF] This article has been cited by other articles: H. G. Klein Transfused B19V: B-nign, B-ware, B-gone? Blood, October 22, 2009; 114(17): 3509 - 3511. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020